Medscape: DEA's Schedule I Proposal Targets Synthetic 7-OH, Spares Botanical Kratom — Addiction Specialists Divided

Why it matters

Medscape's clinical coverage of the DEA 7-OH proposal focuses on physician-level concerns: addiction medicine specialists worry that patients dependent on 7-OH products may abruptly face opioid withdrawal and turn to illicit opioids, and some doctors argue the carve-out for botanical kratom is too narrow given kratom's own dependence risk.

The big picture

The DEA's July 2026 notices of intent cover two tracks: concentrated 7-OH products above 0.05% by weight and three synthetic derivatives (mitragynine pseudoindoxyl, MGM-15, and MGM-16). Concentrated 7-OH is 30-40 times more potent at opioid receptors than mitragynine and produces rapid-onset analgesia, euphoria, respiratory depression, and classical opioid-type withdrawal. The carve-out for botanical kratom reflects FDA's prior framing that naturally occurring trace levels differ fundamentally from manufactured extracts.

Key findings

• DEA published two notices of intent on July 6, 2026 to place concentrated 7-OH and three synthetic derivatives in Schedule I (Docket DEA-1570)
• Concentrated 7-OH produces opioid-like effects 30-40 times more potent than mitragynine; Schedule I includes heroin, LSD
• Products containing more than 0.05% 7-OH by weight or more than 1.0mg per article are covered; botanical kratom with trace 7-OH is exempt
• ASAM expressed concern that patients physiologically dependent on 7-OH may transition to illicit opioids following abrupt loss of supply
• APA addiction psychiatry chair called the action 'encouraging' but argued the kratom plant itself should also be restricted given dependence risk
• Enforcement presents challenges since kratom is itself considered unlawful in dietary supplements under existing FDA rules

What they say

"With no proven therapeutic effect and a high potential for harm, 7-OH and related molecules clearly meet the definition of a Schedule I substance," said Dr. Lief Fenno of the American Psychiatric Association's Council on Addiction Psychiatry. ASAM's Dr. Mario San Bartolome added: "The federal government should carefully consider how to help these individuals understand that they may experience opioid withdrawal symptoms and should therefore seek appropriate medical care."

Bottom line

Addiction medicine specialists broadly support the DEA's Schedule I action on 7-OH but are urging concurrent clinical guidance for patients who may be dependent—warning that without it, abrupt loss of supply could drive people toward far more dangerous illicit opioids.